PROJECT REPORT ON  MERCK & CO<br />
INTRODUCTION<br /><ul><li>One of the largest pharmaceutical company in the world both by market capitalization & revenue
Established in 1891 as the United States subsidiary of the German company now known as Merck KGaA
1917 as an independent company
Manufactures & markets broad range of products to improve human & animal health </li></li></ul><li>LOGO<br />
BASIC INFORMATION<br />Industry<br />Founded<br />Headquaters<br />Chairman<br /> President & CEO<br />Pharmaceuticals<br ...
CONTINUED<br />Revenue<br />Operating Income<br />Net Income<br />Total assets<br />Total equity<br />Employees<br /> US$2...
VISION OF MERCK & CO.<br />We make a difference in the lives of people globally through our innovative medicines, vaccines...
MISSION OF MERCK & CO<br />To provide innovative, distinctive products and services that save and improve lives and satisf...
WHAT WE STAND FOR ????<br />Excellence in science and healthcare innovation, with an emphasis on addressing unmet medical ...
CONTINUED<br />Commitment to expand access to our medicines and vaccines, and to improve global health<br />
PRODUCTS WE DEAL IN ….<br />VACCINES<br />PRESCRIPTION PRODUCTS<br />CONSUMER PRODUCTS<br />ANIMAL HEALTH<br />PRESCRIBING...
RESPONSIBILITY OF MERCK & CO.<br />ETHICS & TRANSPARENCY<br />ACCESS<br />ENVIRONMENT<br />COMMUNITY<br />
OBJECTIVE OF MERCK & CO<br />To develop policy positions that guide our activities and advocacy on a range of issues<br />...
CONTINUED<br />To work closely with the many groups and individuals who are also trying to address the complex healthcare ...
PRODUCTS ON THE MARKET<br />Antivenin - for the treatment of Black Widow Spider bites<br />Arcoxia (etoricoxib) - for the ...
CONTINUED<br />Cosopt (dorzolamide and timolol) - reduces intraocular pressure in people with glaucoma or ocular hypertens...
CONTINUED<br />Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic n...
CONTINUED<br />Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy<br />Emend Injection (fosapre...
CONTINUED<br />Fosamax (alendronate) – osteoporosis medication.<br />Fosamax Plus D (alendronate/vitamin D) – osteoporosis...
COMMON ST. OF MERCK & CO<br />
REVENUE GRAPH OF MERCK & CO.<br />
COMPETITORS IN UK<br />NAMEOF THE COMPANY<br />TOTAL REVENUE<br />     (IN USD BILLIONS)<br />45.83<br />32.81<br />GlaxoS...
COMPETITORS IN USA<br />NAME OF THE COMPANY<br />Johnson & Johnson<br />Abbott Laboratories<br />Pfizer<br /> Eli lilly<br...
COMPETITORS IN SWITZERLAND<br />NAME OF THE COUNTRY<br />HOFFMAN LA ROCHE<br />NOVARTIS<br />NYCOMED<br />      TOTAL REVE...
COMPETITORS IN GERMANY<br />NAME OF THE COUNTRY<br />BAYER<br />BOEHRINGER INGELHEIM<br />MERCK kGaA<br />      TOTAL REVE...
COMPETITORS IN JAPAN<br />NAME OF THE COUNTRY<br />TAKEDAPHARMACEUTICAL<br />ASTELLAS PHARMA<br />DAIICHI  SANKYO 9       ...
SELECTIVE PRODUCT :LISINOPRIL<br />It is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primari...
SYSTEMATIC  IMAGE<br />
IDENTIFIERS<br />CAS number<br />ATC code<br />PubChemode<br />8C09AA03<br />3915-83-7<br />CID 5362119<br />
CHEMICAL DATA<br />Formula <br />Mol. Mass<br />SMILES<br />InChISynonyms<br />C21H31N3O5 <br />405.488 g/mol<br />Emolecu...
Pharmacology<br />Lisinopril is the lysine-analog of enalapril<br />Lisinopril is not a pro drug and is excreted unchanged...
CLINICAL USE<br />Its indications, contraindications and side effects are as those for all ACE inhibitors<br />Its long ha...
CONTINUED<br />For patients whose creatinine clearance is less than 10 mL/min, the dosage should start at 2.5 mg/day, adju...
ADVERSE EFFECTS<br />Chills, infection<br />Dark urine, decreased urination <br />Difficulty swallowing or breathing <br /...
CONTINUED<br />Rapid weight gain, stomach pain<br />Yellowing of skin or eyes (jaundice)<br />Abdominal pain, bloating, vo...
CONTINUED<br />Dry cough<br />Fever<br />Joint pain<br />Rash<br />Diarrhea, loss of taste, nausea<br />
REVENUE OF LISINOPRIL<br />
Upcoming SlideShare
Loading in...5
×

Merck & co

1,534

Published on

MERCK & CO: INTRODUCTION,,REVENUE & MARKET SHARE OF CO,,,COMPETITORS IN 5 COUNTRIES,,PRODUCT CATEGORY,,INTRODUCTION,,REVENUE & MARKET SHARE OF PRODUCT

Published in: Education
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,534
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
39
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Merck & co

  1. 1. PROJECT REPORT ON MERCK & CO<br />
  2. 2. INTRODUCTION<br /><ul><li>One of the largest pharmaceutical company in the world both by market capitalization & revenue
  3. 3. Established in 1891 as the United States subsidiary of the German company now known as Merck KGaA
  4. 4. 1917 as an independent company
  5. 5. Manufactures & markets broad range of products to improve human & animal health </li></li></ul><li>LOGO<br />
  6. 6. BASIC INFORMATION<br />Industry<br />Founded<br />Headquaters<br />Chairman<br /> President & CEO<br />Pharmaceuticals<br />1891 as a subsidiary of Merck KGaA<br />Whitehouse Station, New Jersey, United States<br />Richard T. clarck<br />Stanley F. Barshay<br />
  7. 7. CONTINUED<br />Revenue<br />Operating Income<br />Net Income<br />Total assets<br />Total equity<br />Employees<br /> US$27.4 Billion<br /> US$4.83 Billion<br /> US$12.9 Billion<br /> US$112 Billion<br />US$59.1 Billion<br />61,500<br />
  8. 8. VISION OF MERCK & CO.<br />We make a difference in the lives of people globally through our innovative medicines, vaccines, and consumer health and animal products. We aspire to be the best healthcare company in the world and are dedicated to providing leading innovations and solutions for tomorrow.<br />
  9. 9. MISSION OF MERCK & CO<br />To provide innovative, distinctive products and services that save and improve lives and satisfy customer needs, to be recognized as a great place to work, and to provide investors with a superior rate of return.<br />
  10. 10. WHAT WE STAND FOR ????<br />Excellence in science and healthcare innovation, with an emphasis on addressing unmet medical needs.<br />Focus on patients and anticipating customers needs<br />
  11. 11. CONTINUED<br />Commitment to expand access to our medicines and vaccines, and to improve global health<br />
  12. 12. PRODUCTS WE DEAL IN ….<br />VACCINES<br />PRESCRIPTION PRODUCTS<br />CONSUMER PRODUCTS<br />ANIMAL HEALTH<br />PRESCRIBING INFORMATION<br />
  13. 13. RESPONSIBILITY OF MERCK & CO.<br />ETHICS & TRANSPARENCY<br />ACCESS<br />ENVIRONMENT<br />COMMUNITY<br />
  14. 14. OBJECTIVE OF MERCK & CO<br />To develop policy positions that guide our activities and advocacy on a range of issues<br />To seek opportunities to adopt industry-leading standards in several areas<br />To strive to communicate clearly and transparently about our positions<br />
  15. 15. CONTINUED<br />To work closely with the many groups and individuals who are also trying to address the complex healthcare challenges that confront us<br />
  16. 16. PRODUCTS ON THE MARKET<br />Antivenin - for the treatment of Black Widow Spider bites<br />Arcoxia (etoricoxib) - for the symptomatic treatment of osteoarthritis<br />Cancidas (caspofungin) - An echinocandins antifungal drug for treatment of Aspergillus and Candida<br />
  17. 17. CONTINUED<br />Cosopt (dorzolamide and timolol) - reduces intraocular pressure in people with glaucoma or ocular hypertension.<br />Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.<br />
  18. 18. CONTINUED<br />Cozaar/Hyzaar (losartan)- used to treat hypertension, to reduce the risk of strokes and to treat diabetic nephropathy.<br />Crixivan (indinavir) – a protease inhibitor HIV medication.<br />Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy.<br />
  19. 19. CONTINUED<br />Emend (aprepitant) – treats vomiting and nausea brought about by chemotherapy<br />Emend Injection (fosaprepitantdimeglumine) - an intravenous drug for nausea and vomiting caused by chemotherapy<br />Emflex (Acemetacin) - a non-steroidal anti-inflammatory drug<br />
  20. 20. CONTINUED<br />Fosamax (alendronate) – osteoporosis medication.<br />Fosamax Plus D (alendronate/vitamin D) – osteoporosis medication<br />Isentress (raltegravir) - HIV integrase inhibitor.<br />
  21. 21. COMMON ST. OF MERCK & CO<br />
  22. 22. REVENUE GRAPH OF MERCK & CO.<br />
  23. 23. COMPETITORS IN UK<br />NAMEOF THE COMPANY<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />45.83<br />32.81<br />GlaxoSmithKline<br /> AstraZeneca<br />
  24. 24. COMPETITORS IN USA<br />NAME OF THE COMPANY<br />Johnson & Johnson<br />Abbott Laboratories<br />Pfizer<br /> Eli lilly<br />Bristol-Myers Squibb<br />TOTAL REVENUE(IN USD BILLIONS )<br />61.90<br />30.76 <br />50.0 <br /><ul><li>21.84</li></ul>18.81<br />
  25. 25. COMPETITORS IN SWITZERLAND<br />NAME OF THE COUNTRY<br />HOFFMAN LA ROCHE<br />NOVARTIS<br />NYCOMED<br /> TOTAL REVENUE<br /> (IN USD BILLIONS)<br />47.35<br />44.27<br />4.26<br />
  26. 26. COMPETITORS IN GERMANY<br />NAME OF THE COUNTRY<br />BAYER<br />BOEHRINGER INGELHEIM<br />MERCK kGaA<br /> TOTAL REVENUE<br /> (IN USD BILLIONS)<br />22.3<br />16.9<br />5.17<br />
  27. 27. COMPETITORS IN JAPAN<br />NAME OF THE COUNTRY<br />TAKEDAPHARMACEUTICAL<br />ASTELLAS PHARMA<br />DAIICHI SANKYO 9 <br />EISAI<br />CHUGAI PHARMACEUTICAL .<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />15.6<br />10.7<br />9<br />5.5<br />2.0<br />
  28. 28. SELECTIVE PRODUCT :LISINOPRIL<br />It is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure, heart attacks and also in preventing renal and retinal complications of diabetes. It has been compared withomapatrilat which is of similar function.<br />
  29. 29.
  30. 30.
  31. 31. SYSTEMATIC IMAGE<br />
  32. 32. IDENTIFIERS<br />CAS number<br />ATC code<br />PubChemode<br />8C09AA03<br />3915-83-7<br />CID 5362119<br />
  33. 33. CHEMICAL DATA<br />Formula <br />Mol. Mass<br />SMILES<br />InChISynonyms<br />C21H31N3O5 <br />405.488 g/mol<br />Emolecules & Pubchem<br />(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid<br />
  34. 34. Pharmacology<br />Lisinopril is the lysine-analog of enalapril<br />Lisinopril is not a pro drug and is excreted unchanged in the urine<br />In cases of overdosage, it can be removed from circulation by dialysis<br />
  35. 35. CLINICAL USE<br />Its indications, contraindications and side effects are as those for all ACE inhibitors<br />Its long half-life allows for once a day dosing which aids patient compliance<br />Patients whose creatinine clearance ≥10 mL/min and ≤30 mL/min should be given the standard 5 mg/day dosage, at first<br />
  36. 36. CONTINUED<br />For patients whose creatinine clearance is less than 10 mL/min, the dosage should start at 2.5 mg/day, adjusted over time according to the patient's blood pressure response<br />
  37. 37. ADVERSE EFFECTS<br />Chills, infection<br />Dark urine, decreased urination <br />Difficulty swallowing or breathing <br />Hoarseness<br />Itching<br />
  38. 38. CONTINUED<br />Rapid weight gain, stomach pain<br />Yellowing of skin or eyes (jaundice)<br />Abdominal pain, bloating, vomiting<br />Chest pain or tightness, dizziness, lightheadedness, fainting (syncope)<br />
  39. 39. CONTINUED<br />Dry cough<br />Fever<br />Joint pain<br />Rash<br />Diarrhea, loss of taste, nausea<br />
  40. 40. REVENUE OF LISINOPRIL<br />
  41. 41. MARKET SHARE OF LISINOPRIL <br />
  42. 42. Thank You<br />Presented By :-<br />REEMA PUNIANI<br /> (M100700046)<br />
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×